Vivoryon Therapeutics N.V. VVY

Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, held its Annual General Meeting (AGM) today at 11:00 a.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appoi

Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update Strategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet negotiations for a potential licensing agreement Gained further insight into varoglutamstat’s unique mechanism of action and therapeutic potential in kidney diseaseFinancial guidance maintained: Vivoryon expects cash and cash equivalents to be sufficient for funding operations into Q4

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at WCN 2026Pronounced treatment effect in high-risk patients, including those with diabetes and lower baseline eGFR supporting plans to advance development in stage 3b/4 diabetic kidney disease (DKD) Company continues to prioritize strategic partnering objectives; active due diligence processes underway

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2026 on Thursday, June 11, 2026. The Company’s

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich, Germany, April 15, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will report full year 2025 financial results and business updates on Thursday, April 23, 2026.

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference: Van Lanschot Kempen Life Sciences ConferenceDate: April 16, 20

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglut

The European stock market has recently experienced a boost, with the pan-European STOXX Europe 600 Index reaching record levels amid a rally in technology stocks and expectations for lower U.S. borrowing costs. This positive momentum creates an intriguing backdrop for investors exploring opportunities in smaller or newer companies, often referred to as penny stocks. Although the term 'penny stock' might seem outdated, these investments can still offer significant growth potential when backed...